番茄社区app

Likelihood of severe maternal morbidity more than 20 times higher versus the general population

10% of patients in trials leading to eli-cel's approval developed MDS or AML

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Regimen tops best historical response rate with chemoimmunotherapy in this setting

Incidence almost identical to that with standard cancer treatment in randomized trials

Responses to pirtobrutinib observed in patients with previously treated disease

Better survival in one registry study, detriment with class I HLA mismatch in another

Reactions from physician and consumer groups were positive, but drugmakers begged to differ

News, features, and commentary about cancer-related issues

Prices slashed by as much as 79%

Pregnant people and those who are immunocompromised most at risk, agency warns

News, features, and commentary about cancer-related issues